Emerging Risk Profile of Lung Cancer Therapy: Diffuse Alveolar Hemorrhage from Osimertinib

Table 2

Summary of previously reported cases of cardiac toxicities of Osimertinib.

Article	Patient age/sex	Onset of symptoms	Symptoms	Diagnosis	Treatment	Outcome
Watanabe et al. [10]	78 F	21 days	Facial and lower extremity edema, dyspnea	Congestive heart failure (CHF)	Withdrawal of medication and diuretics	No recurrence of CHF after drug discontinuation
Oyakawa et al. [11]	84 F	34 weeks	Facial edema	Dilated cardiomyopathy/myocarditis	Withdrawal of medication, diuretics, and GDMT	Improved edema, persistently low EF
Schiefer et al. [12]	62 F	11 months	Asymptomatic	QTc prolongation	Withdrawal of medication	Normalization of QT 5 days after discontinuation, patient died of disease progression in 2 months
Yang et al. [3]	6 patients	Unknown	Asymptomatic	QTc prolongation	Dose reduction in 2 patients	Not described